Stratec SE/€SBS

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Stratec SE

STRATEC SE, headquartered in Birkenfeld, Germany, specializes in designing and manufacturing fully automated analyzer systems, software, and smart consumables for the in-vitro diagnostics and life sciences sectors. Founded in 1979, the company operates through three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment focuses on automated analyzer systems for clinical diagnostics and biotechnology clients; the Diatron segment offers systems and consumables for low-throughput hematology and clinical chemistry applications; and the Smart Consumables segment develops polymer-based consumables for diagnostics and medical applications. STRATEC primarily serves as an original equipment manufacturer (OEM), collaborating with diagnostic companies to develop products marketed under their brands. The company's global presence includes facilities in Switzerland, the United States, Romania, Hungary, Austria, and China. Its strategic positioning is reinforced by long-term partnerships with leading in-vitro diagnostics companies and a comprehensive technology portfolio that spans the entire value chain, from design and development to regulatory approval and production. (,)

Ticker

€SBS
Sector

Primary listing

XETRA

Employees

1,416

Stratec SE Metrics

BasicAdvanced
€389M
26.85
€1.20
0.43
€0.60
1.86%

Bulls say / Bears say

Consolidated sales in Q1 2025 increased by 12.0% to €60.4 million, with the adjusted EBIT margin rising 350 basis points to 8.9%, thanks to double-digit growth in the high-margin Spare Parts and Consumables segment.
First half of 2025 consolidated sales rose 5.8% at constant currency to €118.6 million, driven by a 20.5% increase in Development and Services revenue, which reflects a rebound in the system development deal pipeline.
Management reaffirmed their 2025 outlook for low- to mid-single-digit constant-currency sales growth and an adjusted EBIT margin of 10.0%–12.0%, showing confidence in ongoing operational momentum.
Adjusted EBIT margin declined from 8.8% in H1 2024 to 7.2% in H1 2025, mainly due to negative currency effects and margin pressure.
Sales in the Systems segment slipped from €35.8 million in H1 2024 to €34.9 million in H1 2025, suggesting new product launches have seen slower adoption.
Revenue for Q2 2025 was down 1.0% year-over-year at €58.2 million, and the adjusted EBITDA margin for Q2 dropped 680 basis points to 11.6%, indicating short-term profitability headwinds.
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €SBS

Sign up or log in to buy
Capital at risk
Extended hours trading

Upcoming events

No upcoming events
FAQs